A Study to Compare Tenofovir DF Versus the Combination of Emtricitabine Plus Tenofovir DF for the Treatment of Chronic Hepatitis B in Patients With Normal Alanine Aminotransferase (ALT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Gilead Sciences
ClinicalTrials.gov Identifier:
NCT00507507
First received: July 25, 2007
Last updated: February 12, 2014
Last verified: February 2014
  Purpose

The main objective of the study was to evaluate the antiviral activity of tenofovir disoproxil fumarate (tenofovir DF) monotherapy versus emtricitabine (FTC) plus tenofovir DF combination therapy for the treatment of chronic hepatitis B (HBV) in participants in the immune tolerant phase of HBV infection.

The efficacy of tenofovir DF monotherapy versus FTC plus tenofovir DF combination therapy was evaluated for suppression of the virus (decrease in HBV DNA), serological response (generation of antibodies to the virus), biochemical response (changes in liver enzymes), and the development of drug-resistant mutations. The safety and tolerability of both tenofovir DF monotherapy and FTC plus tenofovir DF were evaluated by routine monitoring for adverse events and changes in laboratory parameters.

Participants were randomized in a 1:1 ratio to receive tenofovir DF monotherapy or FTC plus tenofovir DF. All subjects were to continue on blinded study medication until the last subject reached Week 192. Participants who permanently discontinued study drug (on or before Week 192) were followed for a 24-week treatment-free follow-up period, or until initiation of alternative HBV therapy, whichever occurred first. Subjects who discontinued study drug on or after Week 48 because of hepatitis B surface antigen (HBsAg) loss or seroconversion to antibody to hepatitis B surface antigen (anti-HBs), however, were to have returned for their regularly scheduled through Week 192 and every 16 weeks thereafter until the last subject reached Week 192.


Condition Intervention Phase
Chronic Hepatitis B
Drug: Tenofovir DF
Drug: FTC
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind Study Evaluating Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus the Combination of Emtricitabine and Tenofovir DF for the Treatment of Chronic Hepatitis B

Resource links provided by NLM:


Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Percentage of Participants With HBV DNA < 400 Copies/mL at Week 192 [ Time Frame: Week 192 ] [ Designated as safety issue: No ]
    The percentage of participants with HBV DNA < 400 copies/mL at Week 192 was analyzed. Participants with missing data were considered to have failed to achieve the criteria for evaluation.


Secondary Outcome Measures:
  • Percentage of Participants With HBV DNA < 400 Copies/mL at Weeks 48, 96, and 144 [ Time Frame: Weeks 48, 96, and 144 ] [ Designated as safety issue: No ]
    The percentage of participants with HBV DNA < 400 copies/mL at Weeks 48, 96, and 144 was analyzed. Participants with missing data were considered to have failed to achieve the criteria for evaluation.

  • Percentage of Participants With HBV DNA < 169 Copies/mL at Weeks 48, 96, 144, and 192 [ Time Frame: Weeks 48, 96, 144, and 192 ] [ Designated as safety issue: No ]
    The percentage of participants with HBV DNA < 169 copies/mL at Weeks 48, 96, 144, and 192 was analyzed. Participants with missing data were considered to have failed to achieve the criteria for evaluation.

  • Change From Baseline in HBV DNA at Week 48 [ Time Frame: Baseline to Week 48 ] [ Designated as safety issue: No ]
    The change from baseline in HBV DNA at Week 48 was analyzed.

  • Change From Baseline in HBV DNA at Week 96 [ Time Frame: Baseline to Week 96 ] [ Designated as safety issue: No ]
    The change from baseline in HBV DNA at Week 96 was analyzed.

  • Change From Baseline in HBV DNA at Week 144 [ Time Frame: Baseline to Week 144 ] [ Designated as safety issue: No ]
    The change from baseline in HBV DNA at Week 144 was analyzed.

  • Change From Baseline in HBV DNA at Week 192 [ Time Frame: Baseline to Week 192 ] [ Designated as safety issue: No ]
    The change from baseline in HBV DNA at Week 192 was analyzed.

  • Number of Participants With Normal Alanine Aminotransferase (ALT) at Weeks 48, 96, 144, and 192 [ Time Frame: Weeks 48, 96, 144, and 192 ] [ Designated as safety issue: No ]
    Range of normal ALT was 6 to 34 U/L for females, 6 to 43 U/L for males. Participants with missing data were considered to have failed to achieve the criteria for evaluation.

  • Number of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 48, 96, 144, and 192 [ Time Frame: Weeks 48, 96, 144, and 192 ] [ Designated as safety issue: No ]

    The number of participants with HBeAg loss at Weeks 48, 96, 144, and 192 was analyzed. Loss of HBeAg was defined as change of detectable HBeAg from positive to negative.

    No statistical analysis is presented for Week 48 because no participants met the criteria at that time point.


  • Number of Participants With Seroconversion to Antibody Against HBeAg (Anti-HBe) at Weeks 48, 96, 144, and 192 [ Time Frame: Weeks 48, 96, 144, and 192 ] [ Designated as safety issue: No ]

    The number of participants with seroconversion to anti-HBe at Weeks 48, 96, 144, and 192 was analyzed. Seroconversion to anti-HBe was defined as change of detectable antibody to HBeAg from negative to positive.

    No statistical analysis is presented for Week 48 because no participants met the criteria at that time point.


  • Number of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48, 96, 144, and 192 [ Time Frame: Weeks 48, 96, 144, and 192 ] [ Designated as safety issue: No ]
    The number of participants with HBsAg loss at Weeks 48, 96, 144, and 192 was analyzed. Loss of HBsAg was defined as change of detectable HBsAg from positive to negative.

  • Number of Participants With Seroconversion to Antibody to HBsAg (Anti-HBs) at Weeks 48, 96, 144, and 192 [ Time Frame: Weeks 48, 96, 144, and 192 ] [ Designated as safety issue: No ]
    The number of participants with seroconversion to anti-HBs at Weeks 48, 96, 144, and 192 was analyzed. Seroconversion to anti-HBs was defined as change of detectable antibody to HBsAg from negative to positive.

  • Occurrence of HBV Resistance Mutations [ Time Frame: Baseline to Week 192 ] [ Designated as safety issue: No ]
    The development of HBV resistance mutations (occurrence of conserved site changes and/or polymorphic site changes) was analyzed for the overall study period (through Week 192).


Enrollment: 126
Study Start Date: September 2007
Study Completion Date: August 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Tenofovir DF
Participants were randomized to receive tenofovir DF plus placebo to match FTC once daily.
Drug: Tenofovir DF
Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
Other Name: Viread®
Drug: Placebo
Placebo to match FTC taken once daily
Experimental: FTC+Tenofovir DF
Participants were randomized to receive FTC plus tenofovir DF once daily.
Drug: Tenofovir DF
Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
Other Name: Viread®
Drug: FTC
Emtricitabine (FTC) 200 mg capsule taken orally once daily
Other Name: Emtriva®

  Eligibility

Ages Eligible for Study:   18 Years to 69 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic HBV infection, defined as positive serum HBsAg for at least 6 months or HBsAg positive > 3 months and positive for immunoglobulin G antibody against hepatitis B core antigen
  • 18 through 69 years of age, inclusive
  • Hepatitis B e antigen (HBeAg) positive
  • HBV DNA ≥ 10^8 copies/mL
  • ALT ≤ the upper limit of the normal range (ULN)
  • Willing and able to provide written informed consent
  • Negative serum beta-human chorionic gonadotropin (for females of childbearing potential only)
  • Calculated creatinine clearance ≥ 70 mL/min
  • Hemoglobin ≥ 10 g/dL
  • Neutrophils ≥ 1,500/mm^3
  • No prior oral HBV therapy (eg, nucleotide and/or nucleoside therapy or other investigational agents for HBV infection)

Exclusion Criteria:

  • Pregnant women, women who were breast feeding, or who believed they may have wished to become pregnant during the course of the study
  • Males and females of reproductive potential unwilling to use an effective method of contraception during the study
  • Decompensated liver disease defined as direct (conjugated) bilirubin > 1.2 x ULN, prothrombin time > 1.2 x ULN, platelets < 150,000/mm^3, serum albumin < 3.5 g/dL, or prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, or variceal hemorrhage)
  • Received interferon (pegylated or not) therapy within 6 months of the screening visit
  • Alpha-fetoprotein > 50 ng/mL
  • Evidence of hepatocellular carcinoma
  • Coinfection with hepatitis C virus (by serology), HIV, or hepatitis D virus
  • Significant renal, cardiovascular, pulmonary, or neurological disease
  • Received solid organ or bone marrow transplantation
  • Was currently receiving therapy with immunomodulators (eg, corticosteroids, etc.), investigational agents, nephrotoxic agents, or agents susceptible of modifying renal excretion
  • Had proximal tubulopathy
  • Known hypersensitivity to the study drugs, the metabolites, or formulation excipients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00507507

  Show 45 Study Locations
Sponsors and Collaborators
Gilead Sciences
  More Information

No publications provided

Responsible Party: Gilead Sciences
ClinicalTrials.gov Identifier: NCT00507507     History of Changes
Other Study ID Numbers: GS-US-203-0101
Study First Received: July 25, 2007
Results First Received: May 23, 2013
Last Updated: February 12, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Gilead Sciences:
tenofovir
monotherapy
emtricitabine
combination
hepatitis B

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Chronic
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Tenofovir
Tenofovir disoproxil
Emtricitabine
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Anti-HIV Agents

ClinicalTrials.gov processed this record on October 01, 2014